# A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

> **NCT05677893** · PHASE1 · COMPLETED · sponsor: **Oneness Biotech Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)

## Interventions

- **DRUG:** MBS-COV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05677893
- **Lead sponsor:** Oneness Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-07
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677893, "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05677893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*